Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
161 SEK | +23.28% | +22.71% | +7.26% |
26/04 | Nordic Shares Closed Up Friday; Medicover Series B Climbed Highest | DJ |
26/04 | Transcript : Medicover AB, Q1 2024 Earnings Call, Apr 26, 2024 |
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 54% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company sustains low margins.
- The company is in debt and has limited leeway for investment
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 947.06 times its estimated earnings per share for the ongoing year.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.26% | 2.2B | B+ | ||
-14.92% | 84.68B | B- | ||
+13.30% | 81.12B | C+ | ||
+10.92% | 29.4B | C+ | ||
-12.71% | 16.73B | B | ||
-3.06% | 16.36B | A- | ||
-2.63% | 14.92B | A- | ||
-31.75% | 11.77B | - | - | |
-1.42% | 11.72B | A- | ||
+27.44% | 11.71B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MCOV B Stock
- Ratings Medicover AB